Replies to post #326808 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

Blarcamesine isomer Anavex 1-41



Good luck and GOD bless,

[frrol]

Yes. And as for methylations (and esthers, etc,), those chemistry tricks are usually covered in the IP protection, if defendable.

Our 'direct' S1 agonist competition would come most likely from other novel molecules, just as 2-73 and 3-71 are materially different from each other.

May sound odd (and this is not some mythical "FUD") but such S1 competition would actually be a good problem to have. We should be so 'lucky' :-) We might attract a lot of commercially late competition.